Compounded forms of semaglutide and tirzepatide were being sold by dozens of compounded pharmacies from August to October 2025, months after the FDA declared an end to compounding for those drugs, researchers reported.As Healio previously reported, the FDA removed tirzepatide (Mounjaro/Zepbound, Eli Lilly) from its drug shortage list in December 2024 and semaglutide from its drug shortage list in February…
Source: Healio News
